Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$38.22
$38.12
$19.06
$40.14
$2.99B0.81.34 million shsN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$131.87
$131.87
$68.98
$131.98
$14.05B0.691.53 million shsN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$4.31
+1.1%
$4.47
$3.55
$16.11
$194.72M0.51298,462 shs81,293 shs
Zogenix, Inc. stock logo
ZGNX
Zogenix
$26.68
$26.52
$11.03
$26.90
$1.50B0.893.76 million shs94 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.00%0.00%0.00%0.00%+90.92%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
0.00%-8.40%-15.59%-5.18%-62.17%
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
0.9449 of 5 stars
1.10.00.04.50.01.70.6
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.9626 of 5 stars
4.41.00.00.01.42.50.6
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
0.00
N/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.17
Hold$109.70-16.81% Downside
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
2.82
Moderate Buy$15.60262.37% Upside
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ZGNX, ITCI, YMAB, and DRNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$20.00 ➝ $15.00
5/28/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$21.00 ➝ $18.00
5/19/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $11.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
5/14/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.00
4/22/2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Underperform$3.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
$164.31M18.17N/AN/A$1.84 per share20.77
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
$680.50M20.64N/AN/A$6.15 per share21.44
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
$87.68M2.22N/AN/A$2.05 per share2.10
Zogenix, Inc. stock logo
ZGNX
Zogenix
$81.69M18.36N/AN/A$6.64 per share4.02
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%N/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$29.67M-$0.64N/AN/AN/A-31.84%-30.59%-22.70%8/11/2025 (Estimated)
Zogenix, Inc. stock logo
ZGNX
Zogenix
-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/A

Latest ZGNX, ITCI, YMAB, and DRNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
-$0.22-$0.12+$0.10-$0.12$19.97 million$20.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/AN/AN/AN/AN/A
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/AN/AN/AN/AN/A
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/AN/AN/AN/AN/A
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
N/A
2.46
2.46
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
N/A
7.66
7.51
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
N/A
4.77
4.35
Zogenix, Inc. stock logo
ZGNX
Zogenix
0.88
3.63
4.74

Institutional Ownership

CompanyInstitutional Ownership
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
78.91%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
92.33%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
70.85%
Zogenix, Inc. stock logo
ZGNX
Zogenix
N/A

Insider Ownership

CompanyInsider Ownership
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
10.20%
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
2.60%
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
19.70%
Zogenix, Inc. stock logo
ZGNX
Zogenix
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dicerna Pharmaceuticals, Inc. stock logo
DRNA
Dicerna Pharmaceuticals
30278.13 million70.16 millionOptionable
Intra-Cellular Therapies, Inc. stock logo
ITCI
Intra-Cellular Therapies
560106.52 million103.56 millionOptionable
Y-mAbs Therapeutics, Inc. stock logo
YMAB
Y-mAbs Therapeutics
15045.28 million36.36 millionOptionable
Zogenix, Inc. stock logo
ZGNX
Zogenix
21856.23 million53.92 millionOptionable

Recent News About These Companies

Hwasung Industrial Co Ltd 002460
Orally Inhaled Dihydroergotamine
MRI in Headache
Kratom: What We Know
Alcon (NYSE: ALC)
Longeveron Inc Ordinary Shares - Class A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dicerna Pharmaceuticals stock logo

Dicerna Pharmaceuticals NASDAQ:DRNA

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

Intra-Cellular Therapies stock logo

Intra-Cellular Therapies NASDAQ:ITCI

$131.87 0.00 (0.00%)
As of 04/2/2025

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Y-mAbs Therapeutics stock logo

Y-mAbs Therapeutics NASDAQ:YMAB

$4.30 +0.05 (+1.06%)
As of 07/3/2025 02:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Zogenix stock logo

Zogenix NASDAQ:ZGNX

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.